Arcellx, Inc. (ACLX) is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing groundbreaking immunotherapies for challenging oncological and other complex diseases. The firm boasts a promising pipeline that leverages its proprietary technologies to create innovative treatment solutions aimed at transforming patient care and outcomes. With a strong commitment to advancing the oncology landscape, Arcellx is poised to address unmet medical needs and enhance therapeutic options, reflecting its strategic focus on improving the lives of patients facing rigorous health challenges.